KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bionano Genomics (BNGO) Invested Capital (2017 - 2025)

Bionano Genomics (BNGO) has disclosed Invested Capital for 9 consecutive years, with $44.4 million as the latest value for Q4 2025.

  • Quarterly Invested Capital rose 13.4% to $44.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44.4 million through Dec 2025, up 13.4% year-over-year, with the annual reading at $44.4 million for FY2025, 13.4% up from the prior year.
  • Invested Capital hit $44.4 million in Q4 2025 for Bionano Genomics, down from $53.5 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $377.6 million in Q1 2021 to a low of $39.2 million in Q4 2024.
  • Historically, Invested Capital has averaged $184.4 million across 5 years, with a median of $170.8 million in 2023.
  • Biggest five-year swings in Invested Capital: surged 2860.05% in 2021 and later tumbled 63.2% in 2024.
  • Year by year, Invested Capital stood at $341.1 million in 2021, then decreased by 25.73% to $253.3 million in 2022, then plummeted by 60.52% to $100.0 million in 2023, then tumbled by 60.83% to $39.2 million in 2024, then increased by 13.4% to $44.4 million in 2025.
  • Business Quant data shows Invested Capital for BNGO at $44.4 million in Q4 2025, $53.5 million in Q3 2025, and $49.1 million in Q2 2025.